Element Biosciences has announced over $277 million in Series D investment to support continued development of its DNA sequencing and multi-omics technologies. The oversubscribed round was led by Wellington Management with participation from new and existing investors, including Samsung Electronics, Fidelity, Foresite Capital, funds and accounts advised by T Rowe Price Associates, Inc, and Venrock, […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!